Close Menu

NEW YORK (360Dx) – When Mounir Koussa, CEO of Confer Health, learned that a colleague paid three times more for a pregnancy test to get the result one day sooner, his company began pursuing a new commercial path.

The firm, which last week completed a $9.5 million funding round, had been looking to develop a diagnostic test platform based on gel electrophoresis and DNA nanoswitches that had just a few potential uses.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.